TG Therapeutics (NASDAQ:TGTX) Trading Down 9% – Time to Sell?

Shares of TG Therapeutics, Inc. (NASDAQ:TGTX) fell 9% during trading on Thursday . The stock traded as low as $31.37 and last traded at $31.76. 2,935,558 shares changed hands during trading, a decline of 20% from the average session volume of 3,686,909 shares. The stock had previously closed at $34.90.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. TD Cowen assumed coverage on shares of TG Therapeutics in a report on Tuesday, October 29th. They issued a “buy” rating and a $50.00 price objective for the company. HC Wainwright lifted their price target on TG Therapeutics from $49.00 to $55.00 and gave the company a “buy” rating in a research note on Tuesday, November 5th. B. Riley increased their price target on TG Therapeutics from $29.00 to $34.00 and gave the stock a “buy” rating in a research report on Wednesday, August 7th. Finally, The Goldman Sachs Group boosted their price objective on TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $37.67.

TG Therapeutics Price Performance

The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59. The stock has a market capitalization of $4.60 billion, a PE ratio of -295.37 and a beta of 2.19. The stock’s 50 day moving average is $24.74 and its two-hundred day moving average is $21.07.

TG Therapeutics (NASDAQ:TGTX) last released its earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.01). The firm had revenue of $83.90 million during the quarter, compared to analysts’ expectations of $81.68 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The business’s revenue was down 49.4% compared to the same quarter last year. During the same quarter last year, the business earned $0.73 EPS. On average, equities analysts anticipate that TG Therapeutics, Inc. will post 0.17 EPS for the current fiscal year.

Insiders Place Their Bets

In other TG Therapeutics news, Director Sagar Lonial sold 5,000 shares of the stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $30.44, for a total value of $152,200.00. Following the completion of the sale, the director now owns 100,195 shares in the company, valued at approximately $3,049,935.80. This represents a 4.75 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 10.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. NBC Securities Inc. lifted its position in shares of TG Therapeutics by 58.9% during the third quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 485 shares in the last quarter. Quarry LP raised its holdings in TG Therapeutics by 9.1% in the second quarter. Quarry LP now owns 6,003 shares of the biopharmaceutical company’s stock valued at $107,000 after acquiring an additional 503 shares in the last quarter. Private Advisor Group LLC lifted its stake in TG Therapeutics by 3.9% in the third quarter. Private Advisor Group LLC now owns 14,407 shares of the biopharmaceutical company’s stock worth $337,000 after acquiring an additional 542 shares during the last quarter. Blue Trust Inc. grew its holdings in TG Therapeutics by 127.3% during the 3rd quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 849 shares in the last quarter. Finally, KBC Group NV increased its position in shares of TG Therapeutics by 30.5% in the 3rd quarter. KBC Group NV now owns 4,675 shares of the biopharmaceutical company’s stock valued at $109,000 after purchasing an additional 1,092 shares during the last quarter. Institutional investors and hedge funds own 58.58% of the company’s stock.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.